Skip to main content
SpringerLink
Log in

Hematopoietic Growth Factors in Older Cancer Patients

  • Chapter
  • First Online:
Hematopoietic Growth Factors in Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 157))

Abstract

Approximately 80% of all malignancies arise in individuals over age 60 [1]. While evidence suggests that chemosensitivity of certain neoplasms may diminish with increasing age [2, 3], similar benefits from systemic chemotherapy have been observed regardless of age, provided adequate treatment doses are employed [4–8]. Nevertheless, older age remains an independent risk factor for substantial reductions in chemotherapy relative dose intensity (RDI) [9], potentially resulting in compromised outcomes. Reduction in chemotherapy dosing for elderly patients is not entirely unfounded.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.

    Article  PubMed  Google Scholar 

  2. Extermann M. Acute leukemia in the elderly. Clin Geriatr Med. 1997;13:227–44.

    CAS  PubMed  Google Scholar 

  3. O’Reilly SE, Connors JM, Howdel S, et al. Malignant lymphomas in the elderly. Clin Geriatr Med. 1997;13:251–64.

    PubMed  Google Scholar 

  4. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295–305.

    CAS  PubMed  Google Scholar 

  5. Sargent DJ, Goldberg RM, Jacobson MD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.

    Article  CAS  PubMed  Google Scholar 

  6. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.

    Article  CAS  Google Scholar 

  7. Elkin EB, Hurria A, Mitra D, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757–64.

    Article  PubMed  Google Scholar 

  8. Giordano SH, Duan Z, Kuo JF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24:2750–6.

    Article  PubMed  Google Scholar 

  9. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005;10:427–37.

    Article  PubMed  Google Scholar 

  10. Kuderer NM, Dale D, Crawford J, Cosler L, Lyman GH. The morbidity, mortality and cost of febrile neutropenia in cancer patients. Cancer. 2006;106:2258–66.

    Article  PubMed  Google Scholar 

  11. Lyman GH, Dale D, Crawford J. Incidence, practice patterns, and predictors of low dose intensity in adjuvant breast cancer chemotherapy: results of a nationwide survey of community oncology practices. J Clin Oncol. 2003;21; 4524–4531.

    Article  PubMed  Google Scholar 

  12. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictions of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphomas. J Clin Oncol. 2004;22:4302–11.

    Article  CAS  PubMed  Google Scholar 

  13. Lyman GH, Lyman C, Ogboola Y. Risk models for the prediction of chemotherapy-induced neutropenia. Neutropenia Oncol. 2001;1:2–7.

    Google Scholar 

  14. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412–22.

    CAS  PubMed  Google Scholar 

  15. Chrischilles E, Delgado DI, Stolshek BS, et al. Impact of age and colony stimulating factor use in hospital length of stay for febrile neutropenia in CHOP treated non-Hodgkin’s lymphoma patients. Cancer Control. 2002;9:203–21.

    PubMed  Google Scholar 

  16. Kuderer NM, Crawford J, Dale DC, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158–67.

    Article  CAS  PubMed  Google Scholar 

  17. Crawford J, Armitage J, Balducci L et al: Myeloid Growth Factors v.1.2009. J Natl Comp Cancer Netw 2009; 7:64–83.

    CAS  Google Scholar 

  18. Zinzani PG, Storti S, Zaccaria A, et al. Elderly aggressive histology non-Hodgkin’s lymphoma: first line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33–8.

    CAS  PubMed  Google Scholar 

  19. Doorduijn JK, van der Holt B, van der Hem KG, et al. Randomized trials of granulocyte-colony stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin’s lymphoma. Blood. 2000;96:133a.

    Google Scholar 

  20. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–8.

    Article  CAS  PubMed  Google Scholar 

  21. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3041–50.

    Article  CAS  PubMed  Google Scholar 

  22. Bucaneve G, Micozzi A, Menichetti F, et al. The Cruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program: Levofloxacin to prevent bacterial infections in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.

    Article  CAS  PubMed  Google Scholar 

  23. Shayne M, Lichtman MA. Hematology in older persons. In: Lichtman MA, Beutler E, Kipps TJ, et al., editors. Williams hematology. 7th ed. New York, NY: McGraw-Hill Professional; 2005.

    Google Scholar 

  24. Ligthart GJ, Corberand JX, Fournier C, et al. Admission criteria for immunogerontological studies in man: The SENIEUR protocol. Mech Aging Dev. 1984;28:47.

    Article  CAS  PubMed  Google Scholar 

  25. Balducci L, Hardy CL, Lyman GH. Hemopoiesis and aging. Cancer Treat Res. 2005;124:109–34.

    Article  PubMed  Google Scholar 

  26. Shank WA Jr, Balducci L. Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc. 1992;40:151.

    PubMed  Google Scholar 

  27. Oakley E, Miller A, Waterstrat A, et al. Stem cell aging: potential effects on aging and mortality. In: Balducci L, Ershler WB, Bennett JN. Anemia in the elderly. New York, NY: Springer; 2007. pp. 1–20.

    Chapter  Google Scholar 

  28. Haylock DN, Nilsson SK. Hematopoietic microenvironment and age. In: Balducci L, Ershler WB, DeGaetano G. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 71–83.

    Google Scholar 

  29. Qualitative LF. Changes of hematopoiesis. In: Balducci L, Ershler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 95–118.

    Google Scholar 

  30. Albright JW, Makinodan T. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice. J Exp Med. 1976;144:1204–13.

    Article  CAS  PubMed  Google Scholar 

  31. Balducci L, Hardy CL. Aging and hemopoietic stress. In: Balducci L, Ershler WB, DeGaetano G. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 120–8.

    Google Scholar 

  32. Moscinski L. The aging bone marrow. In: Balducci L, Lyman GH, Ershler WB. Comprehensive geriatric oncology. London: Harwood Academic Publishers; 1998. pp. 414–23.

    Google Scholar 

  33. Htwe TH, Mushtaq A, Robinson SB, et al. Infection in the elderly. Infect Dis Clin N Am. 2007;21:711–43.

    Article  Google Scholar 

  34. Chatta CS, Price TH, Allen RC, et al. Effects of “in vivo” recombinant methionyl human granulocyte colony-stimulating factor on the immune response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood. 1994;84:2923–9.

    CAS  PubMed  Google Scholar 

  35. Ferrucci L, Balducci L. Anemia of aging: the role of chronic inflammation and cancer. Sem Hematol. 2008;45:242–9.

    Article  Google Scholar 

  36. Balducci L. Pharmacology of antineoplastic medications in older cancer patients. Oncology. 2009;23:78–85.

    PubMed  Google Scholar 

  37. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007;110:1611–20.

    Article  PubMed  Google Scholar 

  38. Marley SB, Lewis JL, Davidson RJ, et al. Evidence for a continuous decline in hemopoietic cell function from birth: application to evaluating bone marrow failure in children. Br J Haematol. 1999;106:162–6.

    Article  CAS  PubMed  Google Scholar 

  39. Bagnara GP, Bonsi L, Strippoli P, et al. Hemopoiesis in healthy old people and centenarian; well maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. J Gerontol A Biol Sci Med Sci. 2000;55:B61–B70.

    CAS  PubMed  Google Scholar 

  40. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol/Oncol Clin N Am. 2000;14:45–61.

    Article  CAS  Google Scholar 

  41. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med. 2005;118(11):1288–94.

    Article  PubMed  Google Scholar 

  42. Ferrucci L, Guralnik JM, Bandinelli S, et al. Unexplained anaemia in older persons is characterized by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol. 2007;136:849–55.

    Article  CAS  PubMed  Google Scholar 

  43. Tasaki T, Ohto H, Noguchi M, et al. Iron and erythropoietin measurements in autologous blood donors with anemia: implications for management. Transfusion. 1994;34:337–43.

    Article  CAS  PubMed  Google Scholar 

  44. Kumagai T, Morimoto K, Saitoh H, et al. Age-related changes in myelopoietic response to lipopolysaccaride in senescence-accelerated mice. Mech Ageing Dev. 2000;112:153–7.

    Article  CAS  PubMed  Google Scholar 

  45. Boggs DR, Patrene KD. Hematopoiesis and aging III: anemia and a blunted erythropoietic response to hemorrhage in aged mice. Am J Hematol. 1985;19:327–41.

    Article  CAS  PubMed  Google Scholar 

  46. Morra L, Moccia F, Mazzarello GP, et al. Defective burst-promoting activity of T lymphocytes from anemic and non-anemic elderly people. Ann Hematol. 1994;68:67–71.

    Article  CAS  PubMed  Google Scholar 

  47. Hyrota Y, Okamura S, Kimura N, et al. Hematopoiesis in the aged as studied by “in vitro” colony assay. Eur J Haematol. 1988;40:83–90.

    Article  Google Scholar 

  48. Joosten E, Van Hove L, Lesaffre E, et al. Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia. J Am Ger Soc. 1993;41:1301–4.

    CAS  Google Scholar 

  49. Nafziger J, Pailla K, Luciani L, et al. Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly. Am J Hematol. 1993;43:172–6.

    Article  CAS  PubMed  Google Scholar 

  50. Chatta DS, Dale DC. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging. 1996;9:37–47.

    Article  CAS  PubMed  Google Scholar 

  51. Cascinu S, Del Ferro E, Fedeli A, et al. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatin-associated anemia. Oncology. 1995;52:422–6.

    Article  CAS  PubMed  Google Scholar 

  52. Fields KK, Djulbegovic B. Hematopoietic stem cell transplantation in the older patient. In: Balducci L, Lyman GH, Ershler WB, Extermann M, editors. Comprehensive geriatric oncology. London: Taylor and Francis; 2004. pp. 489–500.

    Google Scholar 

  53. Kersting S, Verdonck LF. Successful outcome of nonmyeloablative allogeneic bone marrow transplant in patients with kidney dysfunction. Biol Blood Marrow Transplant. 2008;14:1312–16.

    Article  PubMed  Google Scholar 

  54. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83:614–17.

    Article  PubMed  Google Scholar 

  55. Baker SD, Grochow L. Pharmacology of cancer: chemotherapy in the older person. Clin Geriatr Med. 1997;13:169–83.

    CAS  PubMed  Google Scholar 

  56. Duthie EH. Physiology of aging: relevance to symptoms, perceptions, and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. Amsterdam: Harwood Academic Publishers; 1998. pp. 247–62.

    Google Scholar 

  57. Balducii L, Hardy CH. Anemia of aging: a model of cancer-related anemia. Cancer Control JHLMCC. 1998;5(Suppl):17–21.

    Google Scholar 

  58. Begg CB, Carbone P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer. 1983;52:1986–92.

    Article  CAS  PubMed  Google Scholar 

  59. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 year old with advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2:1406–14.

    Google Scholar 

  60. Christman K, Muss HB, Case D, et al. Chemotherapy of metastatic breast cancer in the elderly. JAMA. 1992;268:57–62.

    Article  CAS  PubMed  Google Scholar 

  61. Giovannozzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois Cancer Center Study. J Clin Oncol. 1994;12:2447–52.

    Google Scholar 

  62. Ibrahim N, Frye DK, Buzdar AU, et al. Doxorubicin based combination chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996;156:882–8.

    Article  CAS  PubMed  Google Scholar 

  63. Ibrahim NK, Buzdar AU, Asmar L, et al. Doxorubicin based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience with long term follow-up. Ann Oncol. 2000;11:1–5.

    Article  Google Scholar 

  64. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of chemotherapy low dose intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302–11.

    Article  CAS  PubMed  Google Scholar 

  65. Chrischilles EA, Link BK, Scott SD, et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control. 2003;10:396–403.

    PubMed  Google Scholar 

  66. Kim YJ, Rubenstein EB, Rolston KV, et al. Colony-stimulating factors (CSFs) may reduce complications and death in solid tumor patients with fever and neutropenia. Proc ASCO. 2000;19:612a. Abstract 2411.

    Google Scholar 

  67. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18(7):1412–22.

    CAS  PubMed  Google Scholar 

  68. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Ger Soc. 1984;32:269–73.

    CAS  Google Scholar 

  69. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte–macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998;16:2352–8.

    CAS  PubMed  Google Scholar 

  70. Bastion Y, Blay J-Y, Divine M, et al. Elderly patients with aggressive non-Hodgkin’s lymphoma: disease presentation, response to treatment and survival. A Groupe d’Etude des Lymphomes de l’Adulte Study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945–53.

    CAS  PubMed  Google Scholar 

  71. Zinzani PG, Storti S, Zaccaria A, et al. Elderly aggressive histology non-Hodgkin’s lymphoma: first Line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33–8.

    CAS  PubMed  Google Scholar 

  72. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol. 1995;13:2530–9.

    CAS  PubMed  Google Scholar 

  73. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate and high grade non-Hodgkin’s lymphoma: results of a randomized study of the European organization for the Research and Treatment of Cancer Lymphoma Cooperative Study. J Clin Oncol. 1998;16:27–34.

    CAS  PubMed  Google Scholar 

  74. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101:3840–8.

    Article  CAS  PubMed  Google Scholar 

  75. Doorduijn JK van derr Holt B, van der hem KG, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3041–50.

    Article  CAS  PubMed  Google Scholar 

  76. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:2386–93.

    CAS  PubMed  Google Scholar 

  77. Melchert M, Lancet J. Acute myeloid leukemia in the elderly. In: Balducci L, Ershler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 237–55.

    Google Scholar 

  78. Balducci L. Consequences of chronic anemia in the older person. In: Balducci L, Ershler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 192–202.

    Google Scholar 

  79. Hardy SE Studenski SA. Fatigue predicts mortality in older adults. J Am Ger Soc. 2008;56:1910–14.

    Article  Google Scholar 

  80. Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol Med Sci. 2008;63:1389–92.

    Google Scholar 

  81. Marcantonio ER, Flacker JM, Michaels M, et al. Delirium is independently associated with poor functional recovery after hip fracture. J Am Ger Soc. 2000;48:618–24.

    CAS  Google Scholar 

  82. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet. 2003;42:779–91.

    Article  CAS  PubMed  Google Scholar 

  83. Atti AR, Palmer K, Volpato S, et al. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging. 2006;27:278–84.

    Article  CAS  PubMed  Google Scholar 

  84. Penninx BW, Pluijm SM, Lips P, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Ger Soc. 2005;53:2106–11.

    Article  Google Scholar 

  85. Shah RC, Wilson RS, Tang Y, et al. Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology. 2009;32:40–6.

    Article  PubMed  Google Scholar 

  86. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335–40.

    CAS  PubMed  Google Scholar 

  87. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin’s lymphoma treated with combination chemotherapy. Ann Oncol. 1994;5(Suppl 2):127–32.

    PubMed  Google Scholar 

  88. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin’s lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leukem Lymphoma. 1996;22:483–93.

    Article  CAS  Google Scholar 

  89. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–24.

    Article  CAS  PubMed  Google Scholar 

  90. Rowe JM, Andersen JW, Mazza JJ, et al. Randomized placebo-controlled phase III study of granulocyte–macrophage colony stimulating factor in adult patients (>55–70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–62.

    CAS  PubMed  Google Scholar 

  91. Heil D, Hoelzer D, Sanz MA, et al. A randomized double blind placebo controlled phase III study of filgrastim in remission induction and consolidation therapy for patients with “de novo” acute myeloid leukemia. The International Acute Leukemia Study Group. Blood. 1997;90:4710–18.

    CAS  PubMed  Google Scholar 

  92. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission-induction chemotherapy in patients aged 61 and older with acute non-lymphocytic leukemia: final report of AML-11 a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer and the Dutch Belgian Hematology Oncology Cooperative Group. Blood. 1997;90:2952–61.

    CAS  PubMed  Google Scholar 

  93. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte–macrophage colony stimulating factor associated induction treatment of acute myelogenous leukemia: a randomized study by the European Organization for Research and Treatment of Leukemia Cooperative Group. J Clin Oncol. 1996;14:2150–9.

    CAS  PubMed  Google Scholar 

  94. Witz F, Sadoun A, Perrin MC. A placebo-controlled study of recombinant human granulocyte macrophage colony-stimulating factor administered during an induction treatment for “de novo” acute myelogenous leukemia in older patients. Blood. 1998;15:2722–30.

    Google Scholar 

  95. Stone RM, Berg DT, George SL, et al. Granulocyte–macrophage colony stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671–7.

    Article  CAS  PubMed  Google Scholar 

  96. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med. 1995;332:1678–83.

    Article  CAS  PubMed  Google Scholar 

  97. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood. 1994;83:2086–92.

    CAS  PubMed  Google Scholar 

  98. Godwin JE, Kapecky KJ, Head JR, et al. A double blind placebo controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myelogenous leukemia. Blood. 1998;91:3607–15.

    CAS  PubMed  Google Scholar 

  99. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865–74.

    CAS  PubMed  Google Scholar 

  100. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211–20.

    CAS  PubMed  Google Scholar 

  101. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5(5):353–60.

    Article  CAS  PubMed  Google Scholar 

  102. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914–24.

    Article  CAS  PubMed  Google Scholar 

  103. Bohlius J, Engert A, Schwarzer G. Erythropoiesis stimulating agents in the treatment of cancer-related anemia. JAMA. 2008;300:2854–2855.

    Article  CAS  PubMed  Google Scholar 

  104. Bennett CL, Luminari S, Nissenson AR, et al. Pure red blood cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403–8.

    Article  CAS  PubMed  Google Scholar 

  105. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205.

    Article  CAS  PubMed  Google Scholar 

  106. LeDeley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007;25:292–300.

    Article  CAS  Google Scholar 

  107. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol. 2007;25(24):3699–704.

    Article  CAS  PubMed  Google Scholar 

  108. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25(25):3871–6.

    Article  PubMed  Google Scholar 

  109. Timmer-Bonte JN, de Boo TM, Smit AJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol. 2005;23:7974–84.

    Article  CAS  PubMed  Google Scholar 

  110. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44:2069–76.

    Article  CAS  PubMed  Google Scholar 

  111. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CHOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402–9.

    Article  PubMed  Google Scholar 

  112. Chen-Hardee S, Chrischilles EA, Voelker MS, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control. 2006;17:647–54.

    Article  PubMed  Google Scholar 

  113. Shayne M, Culakova E, Wolff DA, et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Breast Cancer Res Treat. 2006;100:S281.

    Article  Google Scholar 

  114. Carcia-Carbonero R, Mayadomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31–38.

    Article  Google Scholar 

  115. Lyman GH, Kuderer N, Balducci L. Cancer care in the elderly: cost and quality of life considerations. Cancer Control. 1998;5:347–54.

    PubMed  Google Scholar 

  116. Silber JH, Fridman M, DiPaula RS, et al. Modeling the cost-effectiveness of granulocyte-stimulating factor use in early-stage breast cancer. J Clin Oncol. 1998;16:2435–44.

    CAS  PubMed  Google Scholar 

  117. Bonnadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901–6.

    Article  Google Scholar 

  118. Lyman GH. Risk assessment in oncology clinical practice: from risk factors to risk model. Oncology. 2003;17:8–13.

    PubMed  Google Scholar 

  119. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–205.

    Article  CAS  PubMed  Google Scholar 

  120. Repetto L, Bigansoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of the colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39:2264–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Rochester, Rochester, NY, 14607, USA

    Michelle Shayne

  2. Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA

    Lodovico Balducci

Authors
  1. Michelle Shayne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lodovico Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Shayne .

Editor information

Editors and Affiliations

  1. Department of Medicine, Duke University and the Duke Comprehensi, Durham, 27705, North Carolina, USA

    Gary H. Lyman

  2. Health Sciences Center, Department of Medicine, University of Washington, Seattle, 98195, Washington, USA

    David C. Dale

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shayne, M., Balducci, L. (2010). Hematopoietic Growth Factors in Older Cancer Patients. In: Lyman, G., Dale, D. (eds) Hematopoietic Growth Factors in Oncology. Cancer Treatment and Research, vol 157. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7073-2_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-7073-2_21

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-7072-5

  • Online ISBN: 978-1-4419-7073-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation